KR
Krystal Biotech
KRYS · NASDAQ
$336.68 -0.69% (-$2.33)
1M +0.28%
Market Cap $9.93B
P/E Ratio 41.10x
Div. Yield -
ROE 19.34%
Bulios Fair Price
$285.58
15.2% downside
Current Price
$336.68
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KRYS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
18 /100
Expensive P/FCF 38.50x
P/E 41.10x
P/B 7.30x
Growth
100 /100
Growing Book val. growth 32.67%
FCF growth N/A
EPS growth N/A
Profitability
100 /100
Strong Op. margin 44.93%
Gross margin 93.34%
FCF margin 58.52%
Quality
78 /100
Excellent ROA 16.09%
ROIC 15.34%
Asset turnover 0.29x
Debt
100 /100
Low Net debt/EBITDA -1.92x
Debt/Equity 0.01x
Current ratio 8.32x
Stability
41 /100
Moderate Profitable years 3
Beta 0.54x
EPS volatility 318.68%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KRYS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Krish S. Krishnan
Employees
295
Headquarters
Pittsburgh
Upcoming events
02 NOV
Earnings
Upcoming earnings report